ValiRx (LON:VAL – Get Free Report) released its quarterly earnings results on Tuesday. The company reported GBX (0.09) earnings per share (EPS) for the quarter, Digital Look Earnings reports. ValiRx had a negative net margin of 6,548.06% and a negative return on equity of 71.49%.
ValiRx Trading Up 0.7%
VAL opened at GBX 0.15 on Thursday. The company’s 50 day moving average is GBX 0.15 and its 200 day moving average is GBX 0.21. The company has a market cap of £1.93 million, a price-to-earnings ratio of -0.27 and a beta of 0.59. ValiRx has a 12-month low of GBX 0.13 and a 12-month high of GBX 0.75.
About ValiRx
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Recommended Stories
- Five stocks we like better than ValiRx
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
